Reproducibility of Her2/neu scoring in gastric cancer and assessment of the 10% cut-off rule

Cancer Medicine

Volumn 4, Issue 2, 2015, Pages 235-244

  Behrens, Hans Michael ^a,b   Warneke, Viktoria S ^a   Böger, Christine ^a   Garbrecht, Nele ^a   Jüttner, Eva ^a   Klapper, Wolfram ^a   Mathiak, Micaela ^a   Oschlies, Ilske ^a   Rudolph, Ursula ^a   Stuhlmann Laeisz, Christiane ^a   Trick, David ^a   Röcken, Christoph ^a   Hufnagl, Peter ^b  

^a UNIVERSITY OF KIEL   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Cut off value; Gastric cancer; Her2 neu; Virtual microscopy; Visual perception

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; TRASTUZUMAB; TUMOR MARKER;

ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MICROSCOPE; MICROSCOPY; PATHOLOGIST; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY CONTROL; REPRODUCIBILITY; STOMACH CANCER; VIRTUAL MICROSCOPY; ATTITUDE TO HEALTH; DEVICES; LABORATORY DIAGNOSIS; PATHOLOGY; STOMACH NEOPLASMS;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; FALSE POSITIVE REACTIONS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MICROSCOPY; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS; STOMACH NEOPLASMS; TRASTUZUMAB;

EID: 84964693460     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.365     Document Type: Article

References (25)

1. Bang, Y. J., C. E. Van, A. Feyereislova, H. C. Chung, L. Shen, A. Sawaki, et al. 2010. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687-697.
2. Chua, T. C., and N. D. Merrett . 2012. Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes-a systematic review. Int. J. Cancer 130:2845-2856.
3. Bilous, M., R. Y. Osamura, J. Ruschoff, M. van de Viver, W. Hanna F. Penault-Llorca, et al. 2010. HER-2 amplification is highly homogenous in gastric cancer. Hum. Pathol. 41:304-305.
4. Bozzetti, C., F. V. Negri, C. A. Lagrasta, P. Crafa, C. Bassano, I. Tamagnini, et al. 2011. Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma. Br. J. Cancer 104:1372-1376.
5. Fusco, N., E. G. Rocco, C. C. Del, C. Pellegrini, G. Bulfamante, N. F. Di, et al. 2013. HER2 in gastric cancer: a digital image analysis in pre-neoplastic, primary and metastatic lesions. Mod. Pathol. 26:816-824.
6. Kimura, M., H. Tsuda, D. Morita, E. Shinto, T. Tanimoto, T. Ichikura, et al. 2005. Usefulness and limitation of multiple endoscopic biopsy sampling for epidermal growth factor receptor and c-erbB-2 testing in patients with gastric adenocarcinoma. Jpn. J. Clin. Oncol. 35:324-331.
7. Langer, R., S. Rauser, M. Feith, J. M. Nahrig, A. Feuchtinger, H. Friess, et al. 2011. Assessment of ErbB2 (Her2) in oesophageal adenocarcinomas: summary of a revised immunohistochemical evaluation system, bright field double in situ hybridisation and fluorescence in situ hybridisation. Mod. Pathol. 24:908-916.
8. Abraham, S. C., S. J. Park, J. H. Lee, L. Mugartegui, and T. T. Wu . 2003. Genetic alterations in gastric adenomas of intestinal and foveolar phenotypes. Mod. Pathol. 16:786-795.
9. Kim, M. A., H. J. Lee, H. K. Yang, Y. J. Bang, and W. H. Kim . 2011. Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma. Histopathology 59:822-831.
10. Lee, S., W. B. de Boer, S. Fermoyle, M. Platten, and M. P. Kumarasinghe . 2011. Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections. Histopathology 59:832-840.
11. Tafe, L. J., Y. Y. Janjigian, M. Zaidinski, C. V. Hedvat, M. R. Hameed, L. H. Tang, et al. 2011. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization. Arch. Pathol. Lab. Med. 135:1460-1465.
12. Yan, B., E. X.Yau, S. S. Bte Omar, C. W. Ong, B. Pang, K. G. Yeoh, et al. 2010. A study of HER2 gene amplification and protein expression in gastric cancer. J. Clin. Pathol. 63:839-842.
13. Yan, B., E. X. Yau, S. N. Choo, C. W. Ong, K. J. Yong, B. Pang, et al. 2011. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples. J. Clin. Pathol. 64:880-883.
14. Warneke, V. S., H. M. Behrens, C. Boger, T. Becker, F. Lordick, M. P. Ebert, et al. 2013. Her2/neu testing in gastric cancer: evaluating the risk of sampling errors. Ann. Oncol. 24:725-733.
15. Rüschoff, J., M. Dietel, G. Baretton, S. Arbogast, A. Walch, G. Monges, et al. 2010. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch. 457:299-307.
16. Landis, J. R., and G. G. Koch . 1977. The measurement of observer agreement for categorical data. Biometrics 33:159-174.
17. Fleiss, J. L., B. Levin, and M. C. Paik . 2003. Statistical methods for rates and proportions. 3rd ed. John Wiley & Sons, New York, NY.
18. Gamer, M., J. Lemon, I. Fellows, and P. Singhirr . 2012. irr: various coefficients of interrater reliability and agreement. R package, version 0.84. [computer program].
19. Barnhart, H. X., M. Haber, and J. Song . 2002. Overall concordance correlation coefficient for evaluating agreement among multiple observers. Biometrics 58:1020-1027.
20. Stevenson, M., T. Nunes C. Heuer, J. Marshall, J. Sanchez, R. Thornton, et al. 2013. epiR: An R package for the analysis of epidemiological data. R package, version 0.9-48 [computer program].
21. Hanahan, D., and R. A. Weinberg . 2011. Hallmarks of cancer: the next generation. Cell 144:646-674.
22. Hofmann, M., O. Stoss, D. Shi, R. Buttner, V. van de Vijver, W. Kim, et al. 2008. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 52:797-805.
23. Wolff, A. C., M. E. Hammond, D. G. Hicks, M. Dowsett, L. M. McShane, K. H. Allison, et al. 2013. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J. Clin. Oncol. 31:3997-4013.
24. Gomez-Martin, C., J. C. Plaza, R. Pazo-Cid, A. Salud, F. Pons, P. Fonseca, et al. 2013. Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab. J. Clin. Oncol. 31:4445-4452.
25. Watson, S., P. Validire, P. Cervera, N. Zorkani, A. Scriva, F. Lemay, et al. 2013. Combined HER2 analysis of biopsies and surgical specimens to optimize detection of trastuzumab-eligible patients in eso-gastric adenocarcinoma: a GERCOR study. Ann. Oncol. 24:3035-3039.